Big, contrarian acquisitions are not new territory for Shanghvi. He took bold calls with Taro Pharmaceuticals in 2010 and Ranbaxy Laboratories in 2015, both controversial at the time and both transformative for Sun Pharma. But Organon is different.
For Dilip Shanghvi, Sun Pharma’s Organon acquisition will be the biggest test
Source: Moneycontrol
Read Full Story →
